Glucose and insulin variations in patients during the time course of a FDG-PET study and implications for the "glucose-corrected" SUV

Nuclear Medicine and Biology

Volumn 35, Issue 4, 2008, Pages 441-445

  Hadi, Mohiuddin ^a   Bacharach, Stephen L ^a   Whatley, Millie ^b   Libutti, Steven K ^c   Straus, Stephen E ^d   Rao, V Koneti ^d   Wesley, Robert ^b   Carrasquillo, Jorge A ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

FDG PET; Glucose; Insulin; PET; PET CT; Variability

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN;

ADULT; ARTICLE; BIOASSAY; CORRELATION COEFFICIENT; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TRANSPORT; HUMAN; INSULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; STANDARDIZED UPTAKE VALUE;

BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; FLUORODEOXYGLUCOSE F18; GLUCOSE; HUMANS; INSULIN; NEOPLASMS; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; REFERENCE STANDARDS; TISSUE DISTRIBUTION;

EID: 43049171680     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.02.007     Document Type: Article

References (33)

1. Hustinx R., Benard F., et al. Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med 32 1 (2002) 35-46
2. Rohren E.M., Turkington T.G., et al. Clinical applications of PET in oncology. Radiology 231 2 (2004) 305-332
3. Bastiaannet E., Groen H., et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev 30 1 (2004) 83-101
4. Jadvar H., Gamie S., et al. Musculoskeletal system. Semin Nucl Med 34 4 (2004) 254-261
5. Vansteenkiste J., Fischer B.M., et al. Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. Lancet Oncol 5 9 (2004) 531-540
6. Weber W.A., Schwaiger M., et al. Quantitative assessment of tumor metabolism using FDG-PET imaging. Nucl Med Biol 27 7 (2000) 683-687
7. Huang S.C. Anatomy of SUV. Standardized uptake value. Nucl Med Biol 27 7 (2000) 643-646
8. Minn H., Leskinen-Kallio S., et al. [18F]Fluorodeoxyglucose uptake in tumors: kinetic vs. steady-state methods with reference to plasma insulin. J Comput Assist Tomogr 17 1 (1993) 115-123
9. Paquet N., Albert A., et al. Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med 45 5 (2004) 784-788
10. Sokoloff L., Reivich M., et al. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 28 5 (1977) 897-916
11. O'Rahilly S., Burnett M.A., et al. Haemolysis affects insulin but not C-peptide immunoassay. Diabetologia 30 6 (1987) 394-396
12. Randall A.G., Garcia-Webb P., et al. Interference by haemolysis, icterus and lipaemia in assays on the Beckman Synchron CX5 and methods for correction. Ann Clin Biochem 27 Pt 4 (1990) 345-352
13. Sapin R., Ongagna J.C., et al. Insulin measurements in haemolysed serum: influence of insulinase inhibitors. Clin Chim Acta 274 1 (1998) 111-117
14. Fraser C.G., and Harris E.K. Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 27 5 (1989) 409-437
15. Reivich M., Kuhl D., et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res 44 1 (1979) 127-137
16. Kim C.K., and Gupta N.C. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 17 10 (1996) 890-894
17. Hallett W.A., Marsden P.K., et al. Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med 28 7 (2001) 919-922
18. Freedman N.M., Sundaram S.K., et al. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging 30 1 (2003) 46-53
19. Minn H., Zasadny K.R., et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 196 1 (1995) 167-173
20. Nakamoto Y., Zasadny K.R., et al. Reproducibility of common semi-quantitative parameters for evaluating lung cancer glucose metabolism with positron emission tomography using 2-deoxy-2-[18F]fluoro-d-glucose. Mol Imaging Biol 4 2 (2002) 171-178
21. Stahl A., Ott K., et al. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 31 11 (2004) 1471-1478
22. Langen K.J., Braun U., et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 34 3 (1993) 355-359
23. Lindholm P., Minn H., et al. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 34 1 (1993) 1-6
24. Crippa F., Gavazzi C., et al. The influence of blood glucose levels on [18F]fluorodeoxyglucose (FDG) uptake in cancer: a PET study in liver metastases from colorectal carcinomas. Tumori 83 4 (1997) 748-752
25. Yokoyama I., Inoue Y., et al. Simple quantification of skeletal muscle glucose utilization by static 18F-FDG PET. J Nucl Med 44 10 (2003) 1592-1598
26. Hoekstra C.J., Hoekstra O.S., et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 43 10 (2002) 1304-1309
27. Krak N.C., van der Hoeven J.J., et al. Measuring [(18)F]FDG uptake in breast cancer during chemotherapy: comparison of analytical methods. Eur J Nucl Med Mol Imaging 30 5 (2003) 674-681
28. Roelcke U., Blasberg R.G., et al. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas. J Nucl Med 39 5 (1998) 879-884
29. Hassen K. Oscillations in the blood sugar in fasting normal persons. Acta Med Scand Suppl 4 (1923) 27-33
30. Polonsky K.S., Given B.D., et al. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81 2 (1988) 442-448
31. Lacher D.A., Hughes J.P., et al. Estimate of biological variation of laboratory analytes based on the third national health and nutrition examination survey. Clin Chem 51 2 (2005) 450-452
32. Sebastian-Gambaro M.A., Liron-Hernandez F.J., et al. Intra- and inter-individual biological variability data bank. Eur J Clin Chem Clin Biochem 35 11 (1997) 845-852
33. Chen H., Sullivan G., et al. Assessing the predictive accuracy of QUICKI as a surrogate index for insulin sensitivity using a calibration model. Diabetes 54 7 (2005) 1914-1925